Gensight Biologics SA Cash Flow Conversion Efficiency

Latest as of December 2025: 0.260x

Gensight Biologics SA cash flow conversion efficiency. Based on the latest financial reports, Gensight Biologics SA (SIGHT) has a cash flow conversion efficiency ratio of 0.260x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.49 Million ≈ $-7.59 Million USD) by net assets (€-24.94 Million ≈ $-29.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Gensight Biologics SA (2013–2025)

Cash flow conversion efficiency of Gensight Biologics SA from 2013 to 2025. This chart illustrates how Gensight Biologics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Gensight Biologics SA share price for real-time trading data and today's change.

Gensight Biologics SA Cash Flow Conversion Ratio Explained

Gensight Biologics SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Gensight Biologics SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Gensight Biologics SA ranked by their cash flow conversion efficiency. Also see Gensight Biologics SA market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Yukselen Celik As IS:YKSLN	0.232x
Selva Gida Sanayi AS IS:SELVA	-0.049x
Next Hydrogen Solutions Inc. V:NXH	-0.339x
Guandian Defense Technology Co. Ltd. A SHG:688287	N/A
Hifab Group AB Series B ST:HIFA-B	0.027x
Euroconsultants SA AT:EUROC	0.077x
Master Pack Group Bhd KLSE:7029	0.008x
Vibhor Steel Tubes Limited NSE:VSTL	0.059x

Annual Cash Flow Conversion Efficiency for Gensight Biologics SA (2013–2025)

The table below shows the annual cash flow conversion efficiency of Gensight Biologics SA from 2013 to 2025. Review Gensight Biologics SA (SIGHT) flexibility index to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€-24.94 Million ≈ $-29.16 Million	€-9.38 Million ≈ $-10.96 Million	0.376x	-21.76%
2024-12-31	€-26.92 Million ≈ $-31.47 Million	€-12.94 Million ≈ $-15.12 Million	0.481x	-40.18%
2023-12-31	€-30.70 Million ≈ $-35.89 Million	€-24.66 Million ≈ $-28.83 Million	0.803x	-63.64%
2022-12-31	€-15.28 Million ≈ $-17.86 Million	€-33.75 Million ≈ $-39.46 Million	2.209x	+306.10%
2021-12-31	€15.99 Million ≈ $18.69 Million	€-17.14 Million ≈ $-20.04 Million	-1.072x	+16.87%
2020-12-31	€11.67 Million ≈ $13.64 Million	€-15.04 Million ≈ $-17.59 Million	-1.289x	+46.12%
2019-12-31	€11.75 Million ≈ $13.73 Million	€-28.11 Million ≈ $-32.87 Million	-2.393x	-101.28%
2018-12-31	€23.87 Million ≈ $27.91 Million	€-28.38 Million ≈ $-33.18 Million	-1.189x	-248.17%
2017-12-31	€55.00 Million ≈ $64.30 Million	€-18.78 Million ≈ $-21.96 Million	-0.342x	+7.26%
2016-12-31	€53.34 Million ≈ $62.36 Million	€-19.64 Million ≈ $-22.96 Million	-0.368x	+10.71%
2015-12-31	€29.33 Million ≈ $34.29 Million	€-12.09 Million ≈ $-14.14 Million	-0.412x	+20.91%
2014-12-31	€10.58 Million ≈ $12.37 Million	€-5.52 Million ≈ $-6.45 Million	-0.521x	-353.65%
2013-12-31	€16.97 Million ≈ $19.83 Million	€-1.95 Million ≈ $-2.28 Million	-0.115x	--

About Gensight Biologics SA

PA:SIGHT France Biotechnology

Market Cap

$20.04 Million

€17.14 Million EUR

Market Cap Rank

#24959 Global

#400 in France

Share Price

€0.07

Change (1 day)

-5.31%

52-Week Range

€0.07 - €0.14

All Time High

€9.58